ITT analysis population - RCT
|
|
6
|
1754
|
February 3, 2024
|
Ranked analysis of ANCOVA
|
|
7
|
3069
|
January 21, 2024
|
Bayesian Dynamic Borrowing with Robust Mixture Priors: Fair or not?
|
|
7
|
2300
|
January 18, 2024
|
Language for communicating frequentist results about treatment effects
|
|
200
|
123435
|
January 9, 2024
|
Substituting treatment arm with drug exposure (continuous variable) in RCT
|
|
10
|
1512
|
January 8, 2024
|
Encryption of dataset in REDCap
|
|
3
|
1434
|
December 15, 2023
|
Mixed models modelling
|
|
14
|
2937
|
October 26, 2023
|
Summary Statistics vs Raw Data
|
|
9
|
11125
|
October 23, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
1099
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
1697
|
August 29, 2023
|
Effect modification in series of n-of-1 trials (repeated crossover)
|
|
2
|
1084
|
August 25, 2023
|
Data collected outside of guidelines/window
|
|
10
|
3547
|
June 13, 2023
|
Different results in unconstrained partial proportional odds model
|
|
0
|
1311
|
May 22, 2023
|
Attrition Sensitive Randomisation
|
|
1
|
1437
|
April 25, 2023
|
Randomization in a diagnostic study - necessary?
|
|
3
|
1560
|
March 16, 2023
|
Appropriate model for combined data from two RCTs
|
|
10
|
1306
|
March 8, 2023
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
50
|
9339
|
March 7, 2023
|
FDA "Bad Habits"
|
|
7
|
2519
|
March 4, 2023
|
Resources for handling blocked randomization in the analysis of RCTs
|
|
10
|
5358
|
February 11, 2023
|
Toward Guidelines for RCT Measurements.. What are the characteristics of an acceptable measurement for RCT?
|
|
0
|
1246
|
February 10, 2023
|
Rescue analysis for % change from baseline as an outcome in RCT
|
|
16
|
3686
|
January 16, 2023
|
The Clinical and Statistical Saga of Thrombolysis in Acute Ischemic Stroke
|
|
11
|
3106
|
December 21, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
4001
|
November 21, 2022
|
Is it appropriate to present confidence intervals (CIs) for the outcome in each treatment group in the context of clinical trials?
|
|
5
|
2107
|
November 2, 2022
|
Background to PFS endpoint
|
|
19
|
8166
|
October 6, 2022
|
Quality of remdesivir trials
|
|
54
|
20483
|
October 5, 2022
|
Cdisc in academia
|
|
1
|
1376
|
September 7, 2022
|
Patient-specific treatment effects in RCTs: why should one present them?
|
|
1
|
2606
|
August 13, 2022
|
Which to make as the primary analysis
|
|
1
|
2655
|
July 25, 2022
|
Non-inferiority and choice of scale (absolute vs relative)
|
|
4
|
1911
|
July 23, 2022
|